The principle of X-ray fluorescence (XRF) is the use of photons to fluoresce atoms of the element of interest. Fluoresced atoms can then emit X-rays of energies specific to that element. The number of X-rays is proportional to the amount of the element present in the sample. Both 7-rays from radioisotopes and X-rays from a generator have been used as the fluorescing photons in bone lead measurement systems. The major difference between methods is whether they fluoresce the K-shell or the Lshell electrons of lead. Two of the three reported methods fluoresce K-shell electrons. The difference between K and L lead X-rays is their energy: L X-rays range in energy from 9.2 to 12.6 keV; K X-rays range from 72.8 to 87.3 keV. The energy of the X-rays determines their ability to overcome the effects of attenuation and escape from the body for detection.
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Attenuation is one of the most important factors in any XRF measurement method because both the fluorescing photons (produced by whichever method) and the fluoresced X-rays (be they K-or Lshell) are attenuated by whatever material they pass through. In bone lead measurements, the tissue overlying the bone site and within the bone itself are the regions of principal concern. Attenuation is characterized by the mass attenuation coefficient which depends on the composition of the material and the energy of the photon. For a particular substance and particular photon energy, the mass attenuation coefficient can be used to obtain the more readily understandable quantity of the "mean free path." The mean free path is, as the name suggests, the average distance traveled by a photon before undergoing some form of interaction. In bone lead measurements, the interaction is usually a Compton scattering event, which can reduce the energy of the photon. Compton scattering is undesirable for two reasons. First, the energy of a fluorescing photon is reduced; the resulting scattered photon may no longer have sufficient energy to interact with a lead atom to produce an X-ray. Such scattered photons produce a relatively intense background in the energy spectrum on which lead quantitation is based and are the main limitation on measurement precision. Second, if a fluoresced X-ray is Compton scattered, it no longer has one of the characteristic lead energies and thus contributes further to the background instead of the signal.
In considering attenuation, we broach one of the fundamental differences between K and L XRF: the difference in the volume of bone sampled. In both K and L XRF, attenuation of both fluorescing and fluoresced photons needs to be considered in a rigorous analysis. However, for our purposes a simple illustration will suffice. For the L XRF system, we will ignore attenuation of the fluorescing photons and consider only attenuation of the La X-rays (10.55 keV) because this is the larger effect. The mean free path of these X-rays is 1.5 mm in soft tissue and 0.2 mm in bone. For the K XRF systems that use the 88.035 keV y-ray from 109Cd, the combined effects of attenuation on a fluorescing y-ray and a Kai X-ray (75.0 keV) give a mean free path of 19.0 mm in soft tissue and 9.0 mm in bone. Ignoring attenuation of the L XRF fluorescing photons may underestimate the difference between K and L XRF, but the underestimation is not great. Another illustration of the effect of attenuation is given by the depth at which the sensitivity of a system falls to a certain level, as calculated by Thomas (1) : for L XRF, 30% sensitivity occurs 1.3 mm into bone, for K XRF the distance is approximately 25 mm. Thus, lead La X-rays have difficulty escaping from the body, and the regions of bone lead beyond approximately 2 mm are not sampled.
Similarities and Differences of Practical Measurement Systems
The literature on the measurement of trace and minor elements in vivo has been reviewed elsewhere (2, 3) . The reviews and our previous work (4) fluorescing the L-shell electrons (using 125I or an X-ray generator). In addition to the fluorescing source, the components of an XRF measurement system consist of a radiation detector [of the type most suited to the energy of radiation under study; Ge for K XRF, Si(Li) for L XRF], preamplifier, amplifier, analog-todigital converter, multichannel analyzer, and computer for data storage and analysis. All bone lead measurements are noninvasive; the subject must sit in a chair and have the measurement system moved into place. 109Cd K XRF measurements are typically performed for approximately 30 min, L XRF measurements for 16 min. A recent paper (5) shows a practical measurement being made with a 09Cd K XRF system. Each system is transportable, allowing mobile laboratory facilities to be established.
The first in vivo measurements were performed at the University of Lund, Sweden, using 57Co as the fluorescing source. The measurement site was the phalanx, and the achieved detection limit -iiii I' A. i*lii -fii -9 i iM III (defined as an X-ray peak area equal to three times the standard deviation of the underlying background counts) was approximately 20 pg Pb/g bone wet weight, for an effective dose equivalent (using superseded nomenclature) of approximately 0.1 pSv (6) (7) (8) . The same method has been adopted by the Queensland University of Technology, Australia, also measuring the phalanx (9), and was independently developed at the University of Pennsylvania, where the measurement sites have been teeth, wrist, and temple (10, 11) . The development of L XRF systems to measure lead in bone has been conducted by Brookhaven National Laboratory (12) (13) (14) (25, 26) , the University of Maryland (27, 28) , and Queen Elizabeth Medical Center, Birmingham, UK (29, 30 
Intercomparison of Methods
The two K XRF methods have been used in a collaborative study (31) , where their performances were compared. The 109Cd method gave better precision than the 57Co method (10 jig Pb/g bone mineral versus 50 pg Pb/g bone mineral, respectively), but also delivered a higher effective dose equivalent (0.1 pSv versus 2.1 pSv, respectively) (3, 32) . However, the reported doses from the two systems are not calculated according to the most recent guidelines (see below).
Radiation Dose
All bone lead measurements use radiation, making the radiation dose and its consequent risk important concerns. The dose delivered by all bone lead measurement methods is small. Nevertheless, full radiodosimetric analyses of the 109Cd K XRF and L XRF methods have been performed, using the current methods of dose calculation. The 109Cd K XRF study (20) indicated an effective dose to a 1-year-old child, an adult male, and an adult female of 1.1 pSv, 34 nSv, and 38 nSv, respectively. The L XRF dosimetry for measurements of pregnant women was the focus of a paper by Kalef-Ezra et al. (33) . A full analysis of the L XRF system has also been published (34) , then corrected and updated to the most recent guidelines (35) . The most recent paper (35) indicated an effective dose to a 1-year-old child more than twice as great as that from a 109Cd K XRF measurement and a dose to an adult approximately eight times greater. The dose delivered to a conceptus is lower for L XRF, by a factor of approximately 20 . The differences between the doses of the two methods are less important than their magnitudes: for 109Cd K XRF, the effective dose for a 1-year-old child is equivalent to approximately 3 hr of the average effective dose arising from background radiation (36) ; the additional risk of a cancer mortality (excluding leukemia) is approximately 1 in 10 million (20) . From these facts, it is clear that radiation risk should not be a limiting factor in using either method.
Precision
There is an ever-increasing improvement in the performance of nuclear spectroscopy components, which is partly responsible for the improvements in detection limit reported over recent years. Improvements in measurement precision continue in many laboratories. Currently quoted precisions are in the range of 4-10 jig Pb/g bone, where bone, for L XRF, indicates wet weight, and, for K XRF, indicates bone mineral. For an adult tibia, conversion between the two units requires multiplication of the wet weight value by 1.8; for other bones, the conversion factor is greater. Precision (for all methods) depends on the amount of tissue overlying the bone: the greater the thickness of tissue, the worse the precision. For example, in comparing 3 mm and 6 mm of overlying soft tissue, 109Cd K XRF precision worsens by 5%, L XRF precision worsens by 49%. The precision of the L XRF method is affected by the heavy attenuation of the lead L X-rays. In L XRF, the number of observed X-ray counts is adjusted to the number of counts that would have been observed if the subject had possessed 5 mm of overlying tissue; i.e., the number of X-rays is scaled to correct for the effects of attenuation. The number of X-ray counts sets a limit on precision, but the method of conversion from counts to concentration is also important. Ultrasound measurement of overlying tissue thickness is required with the L XRF method, introducing a further uncertainty arising from the precision of the ultrasound measurement. The precision of ultrasound measurement was reported by the L XRF pioneers to be 0.3 mm (37), resulting in an uncertainty of approximately 13% in the factor used to convert a measurement from counts to concentration. The uncertainty from ultrasound measurement is then added (in quadrature) to that arising from counting statistics. For low bone lead levels, the ultrasound uncertainty is minor; but for high bone lead concentrations, it sets the lower limit to total measurement uncertainty. Table 1 shows the L XRF uncertainty (in terms of wet weight bone) for three different "true" bone lead concentrations. For each entry in Table 1 , the uncertainty from counting statistics is a constant ± pg Pb/g bone wet weight. (Note that counting statistics uncertainty is determined largely by the magnitude of the spectral background, rather than the X-ray peak.) The The same is true for the 57Co K XRF method. The mean free path for the principal lead L X-ray is 0.22 mm in bone, making it particularly sensitive to the heterogeneity in bone lead concentration.
Validation
Both K and L XRF methods have been validated, in each case by comparison between XRF and atomic absorption spectrophotometry (AAS). Validation of '09Cd K XRF was reported by Somervaille et al. (44) . This was an indirect comparison; i.e., bare-bone samples had a core removed for AAS analysis before delivery for 109Cd K XRF measurement. XRF and AAS methods were independently calibrated. Paired analysis between AAS and 109Cd K XRF was conducted on 80 samples: bones from tibia sections, tibia fragments, calcaneus, and metatarsals. The mean difference between 109Cd K XRF and AAS measurements was <0.1 pg Pb/g bone mineral. The largest difference found was for a subset of three tibia fragments, which exhibited a difference of approximately 5 pg Pb/g bone mineral (45) . It should be noted that AAS and 109Cd K XRF sample different average bone masses: 20 mg and 10-15 g, respectively. Validation of bare-bone measurements was thus produced. Validation of intact bone measurements relies on further experiments which indicate that the accuracy of the elastic scatter normalization process is independent of the amount of tissue overlying the bone (46). More limited data for direct validation of 109Cd K XRF for intact, amputated limbs has been reported by Hu et al. (21) , work that appears to confirm the accuracy of the method. Other direct comparison was provided by measurements made on autopsy samples from a subject who had previous 57Co K XRF bone lead measurements (8,4? 
Robustness and Adaptability
In the 109Cd K XRF method, the lead Xrays are normalized to the elastic scatter peak. Normalization yields a measurement accuracy that is independent of several potential confounders: fluorescing source to subject distance, overlying tissue thickness, bone size, bone shape, bone geometry, bone density, nongross differences in interindividual positioning of the measurement apparatus, and minor patient movement. To a greater or lesser extent, the other XRF methods depend onall of these factors. The ability of the 109Cd K XRF method to perform measurements at several different bone sites and to make meaningful comparisons of the results obtained was illustrated by the Birmingham group in an extensive series of studies and collaborations with groups in Sweden and Finland. Together, the studies report the measurement of lead in tibia, calcaneus, wrist, skull, and sternum (18, 31, 44, 46, (48) (49) (50) (51) (52) (53) .
Human Studies Using XRF L XRF measurements have been principally performed on children, although there have been some measurements of occupationally exposed adults (13, 54) . In children, L XRF measurements have been compared to the outcome of a provocative EDTA chelation test, with a view to using the noninvasive and rapid L XRF test as a replacement for the time-consuming chelation test. Methods are presented in the original paper (55); corrected results were republished (56) . When the outcome of the EDTA test, bone lead, and blood lead were all used as categorical variables (i.e., "raised" or "not raised"), blood lead and bone lead exhibited approximately equal power in their abilities to predict the outcome of the EDTA test. In combination, blood lead and bone lead could predict the outcome of the EDTA test in approximately 90% of the 59 cases. In the same children, blood lead correlated slightly more strongly with EDTA lead than did bone lead (Pearson correlation coefficients of 0.701 and 0.472, respectively). The difference between the two was not highly significant (p>>5%). The same data were subsequently presented in a more complete ~~MM report (5) , an earlier version of which (58) contains printing errors and should be disregarded.
In a study of L XRF and chelation in adults, a correlation between L XRF bone lead and chelated lead was also observed (13) . The adult L XRF data were reported to be broadly consistent with the findings of Jones et al. (16) , who used a 109Cd K XRF method. In contrast, Schutz et al. (59) , studying chelatable lead after administration of penicillamine, found no relationship between chelatable lead and 57Co K XRF lead measured in finger bone but did find a relationship between chelatable lead and vertebral bone biopsies. The data of Schutz et al. clearly show that finger bone lead and penicillamine-chelatable lead are closely related only when subjects are in the same exposure status. Retired workers show a much higher ratio of bone lead to chelated lead than active workers. The inference is that whole bone lead, as measured by K XRF, samples a different and longer-term lead compartment than that sampled by the provocative chelation test. More recently, a collaborative project between the groups at Birmingham (using 109Cd K XRF to measure tibia and calcaneus) and Malmo/Lund (using 57Co K XRF to measure phalanx) studied bone lead over a course of EDTA chelation in 20 workers. They found no evidence of statistical significance for a decrease in bone lead measurements of either tibia or calcaneus over the course of chelation. None of the bone sites correlated well with EDTA-chelated lead, although they all correlated well with each other. The strongest indicator of 24-hr chelated lead was found to be prechelation blood lead (r = 0.86; p<0.0001) (60) . The report concluded with support for the argument that EDTA-chelated urinary lead primarily reflects the blood and soft tissue lead pools, rather than the total body burden. These findings invite further research, as they have important implications for understanding studies of blood lead, bone K XRF (50) methods. These relationships allow the inference of the average blood lead level over a defined working lifetime from a single K XRF bone lead measurement. The possibility that skeletal lead stores are eventually released has been the subject of recent discussion (66) (67) (68) . The concern is that lifetime lead stores may act as an endogenous source of lead exposure in later life or during times of elevated bone turnover, as occurs during pregnancy and osteoporosis. Evidence to support the hypothesis that skeletal lead can indeed act as an endogenous source of exposure comes from a handful of K XRF studies (18, 47, 51, 62 
Discussion and Conclusions
We suggest that in vivo measurements of lead in bone will not, ultimately, replace any existing measurements of lead exposure. Rather, they will supplement the existing tests by providing information on lead pools that cannot be otherwise sampled except by biopsy. A possible exception is replacement of the provocative chelation test with an L XRF measurement, if it is confirmed that L XRF measurements do indeed sample the relatively short-term lead pool accessed by provocative chelation.
The radiation doses for K and L methods are so low that they should not be a deciding factor in whether to conduct a study on any population. Improvements in measurement system sensitivity should be accompanied by evaluation of the dose. A recent concern has been the possible interferences to the lead signal in an L XRF measurement (70 =Agge -what precision would be obtained. In our experience, it is likely that the precision of measurements of children's bones will be worse than the precision obtainable from adult bones because the total amount of bone mineral sampled will be less for children. It is unlikely that the degradation in precision would be by as much as a factor of two. This would still make K XRF bone lead measurements valuable in children. With regard to screening, it is our opinion that none of the XRF methods is sufficiently developed to be applied in programs to screen the general population. Some methods are more developed and robust than others, but none is yet ready for widespread application. Nevertheless, bone lead measurements may prove to be, in the future, a valuable screening and even a diagnostic tool for the clinician. 
